Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

home:protocol:olmesartan:kidney_disease [08.13.2019] – [Subclinical kidney infection] sallieqhome:protocol:olmesartan:kidney_disease [09.14.2022] (current) – external edit 127.0.0.1
Line 12: Line 12:
 ===== High BUN is an indication of a successful immune response =====  ===== High BUN is an indication of a successful immune response ===== 
  
-One study found that hemodialysis patients who had high serum values of urea nitrogen (BUN) were less likely to have the acute infection, //Helicobacter pylori//.(({{pubmed>long:14696511}})) This suggests that temporary markers of kidney stress such as BUN may correlate with a robust and successful immune response. +One study found that hemodialysis patients who had high serum values of urea nitrogen (BUN) were less likely to have the acute infection, //Helicobacter pylori//.(({{pmid>long:14696511}})) This suggests that temporary markers of kidney stress such as BUN may correlate with a robust and successful immune response. 
  
  
 ===== Vitamin D Receptor activation increases creatinine production ===== ===== Vitamin D Receptor activation increases creatinine production =====
  
-In a 2011 study appearing in //Kidney International//, Agarwal //et al.// gave 16 patients with chronic kidney disease daily doses of paricalcitol, an orally active vitamin D receptor activator.(({{pubmed>long:21716260}})) The vitamin D analog was stopped after four days, and measurements were continued for three. Researchers found that subjects' serum creatinine significantly increased at a rate of 0.010 mg/dl/day and urine creatinine at a rate of 17.6 mg/day. Researchers also found a small increase in blood levels of BUN. +In a 2011 study appearing in //Kidney International//, Agarwal //et al.// gave 16 patients with chronic kidney disease daily doses of paricalcitol, an orally active vitamin D receptor activator.(({{pmid>long:21716260}})) The vitamin D analog was stopped after four days, and measurements were continued for three. Researchers found that subjects' serum creatinine significantly increased at a rate of 0.010 mg/dl/day and urine creatinine at a rate of 17.6 mg/day. Researchers also found a small increase in blood levels of BUN. 
  
 <blockquote> <blockquote>
Line 25: Line 25:
 </blockquote> </blockquote>
  
-This //in vivo// study is significant as it confirms several key aspects of the Marshall Protocol:(({{pubmed>long:21278764}}))+This //in vivo// study is significant as it confirms several key aspects of the Marshall Protocol:(({{pmid>long:21278764}}))
   * Patients with kidney disease on a treatment designed to stimulate the VDR can expect their measures of creatinine to increase.   * Patients with kidney disease on a treatment designed to stimulate the VDR can expect their measures of creatinine to increase.
   * The strategy of waiting-out abnormal creatinine values, rather than trying to intervene, is the most sensible approach currently available.    * The strategy of waiting-out abnormal creatinine values, rather than trying to intervene, is the most sensible approach currently available. 
Line 40: Line 40:
 <blockquote>In the patient with an increase in serum creatinine concentration, decreasing the dose of [the ARB]... will cause the serum creatinine concentration to return to the original baseline. Unfortunately, such an approach is not optimal for the long-term preservation of renal function and should be discouraged. <blockquote>In the patient with an increase in serum creatinine concentration, decreasing the dose of [the ARB]... will cause the serum creatinine concentration to return to the original baseline. Unfortunately, such an approach is not optimal for the long-term preservation of renal function and should be discouraged.
  
- //**Biff Palmer,** Nephrology at the University of Texas Southwestern// (({{pubmed>long:13679467}})) </blockquote>+ //**Biff Palmer,** Nephrology at the University of Texas Southwestern// (({{pmid>long:13679467}})) </blockquote>
  
-"Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function"  (({{pubmed>long:24062331}})) +"Creatine in meat is converted to creatinine on cooking, which is absorbed, causing significant increases in serum creatinine. This could impact management, as threshold for commencing and withdrawing certain medications and expensive investigations is defined by eGFR. eGFR calculated using fasting serum creatinine would be a better reflection of kidney function"  (({{pmid>long:24062331}})) 
-===== Benefits of olmesartan for patients with kidney disease =====+ 
 +===== Subclinical kidney infection ===== 
 + 
 +Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home:pathogenesis:th1spectrum|Th1 diseases]], and this is no less true of MP patients. Inflammation in the kidney and liver tend to be “silent.” Before beginning the MP, the kidneys are inflamed because they are infected with the [[home:pathogenesis::microbiota|Th1 pathogens]]. Patients tend to be largely unaware of the problem because their immune system, which has been weakened by the pathogens, doesn’t kill enough of the pathogens to cause a rise in bacterial byproducts that would be picked up on a blood test. 
 + 
 +Once patients activate the [[home:pathogenesis:innate_immunity|innate immune system]] with olmesartan and begin rapidly killing the Th1 pathogens, the resulting immunopathology causes a rise in bacterial death, the effects of which are finally high enough to show up on lab tests. 
 +===== Olmesartan benefits patients with kidney disease =====
  
 According to a 2008 commentary appearing in //Nature//: According to a 2008 commentary appearing in //Nature//:
Line 49: Line 55:
 <blockquote>Vitamin D receptor (VDR) activation has a beneficial influence on the progression of experimental renal insufficiency, and reduced renal tissue renin expression may play a role in this process. <blockquote>Vitamin D receptor (VDR) activation has a beneficial influence on the progression of experimental renal insufficiency, and reduced renal tissue renin expression may play a role in this process.
  
- //**Ilkka H. Pörsti**// (({{pubmed>long:19008907}}))</blockquote>+ //**Ilkka H. Pörsti**// (({{pmid>long:19008907}}))</blockquote>
  
 MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage.
Line 55: Line 61:
 The benefits of olmesartan on patients with kidney inflammation include The benefits of olmesartan on patients with kidney inflammation include
  
-  * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed>long:17130263}})) +  * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pmid>long:17130263}})) 
-  * decreased (intra)renal vascular resistance, increased renal perfusion, and significantly reduced oxidative stress in patients with type 2 diabetes(({{pubmed>long:15716329}})) +  * decreased (intra)renal vascular resistance, increased renal perfusion, and significantly reduced oxidative stress in patients with type 2 diabetes(({{pmid>long:15716329}})) 
-  * protection of the kidneys in diabetic nephropathy  (({{pubmed>long:20421884}})) +  * protection of the kidneys in diabetic nephropathy  (({{pmid>long:20421884}})) 
-  * offer a survival benefit in hemodialysis patients, may help in preservation of renal function in predialysis patient, and  affect the tissue repair process, reducing renal fibrosis(({{pubmed>long:20540037}})) +  * offer a survival benefit in hemodialysis patients, may help in preservation of renal function in predialysis patient, and  affect the tissue repair process, reducing renal fibrosis(({{pmid>long:20540037}})) 
-  * prevention of the onset of microalbuminuria in patients with Type 2 diabetes(({{pubmed>long:16508590}})) (({{pubmed>long:21388309}})) (({{pubmed>long:22418908}})) ((HealthCareRepublic. 2010. [[http://www.healthcarerepublic.com/news/1011233/ARB-slows-onset-microalbuminuria/|ARB slows onset of microalbuminuria]].))+  * prevention of the onset of microalbuminuria in patients with Type 2 diabetes(({{pmid>long:16508590}})) (({{pmid>long:21388309}})) (({{pmid>long:22418908}})) ((HealthCareRepublic. 2010. [[https://www.healthcarerepublic.com/news/1011233/ARB-slows-onset-microalbuminuria/|ARB slows onset of microalbuminuria]].))
  
  
Line 66: Line 72:
 <blockquote>High-dose ARB treatment in patients with chronic renal disease is not associated with any clinically significant long-term negative effects on serum creatinine or potassium and is thus an important therapeutic modality with which to achieve further reductions in urinary protein excretion. <blockquote>High-dose ARB treatment in patients with chronic renal disease is not associated with any clinically significant long-term negative effects on serum creatinine or potassium and is thus an important therapeutic modality with which to achieve further reductions in urinary protein excretion.
  
- //**Alan J. Weinberg,** et al.// (({{pubmed>long:16601581}})) </blockquote>+ //**Alan J. Weinberg,** et al.// (({{pmid>long:16601581}})) </blockquote>
  
  
 The effects of ARBs, in general, on people with kidney inflammation include: The effects of ARBs, in general, on people with kidney inflammation include:
  
-  * improved patient prognosis in non-diabetic chronic kidney diseases with mild-to-moderate renal dysfunction.(({{pubmed>long:17653243}}))+  * improved patient prognosis in non-diabetic chronic kidney diseases with mild-to-moderate renal dysfunction.(({{pmid>long:17653243}}))
   * effectiveness in controlling UAE [urinary albumin excretion] in cases in which blood pressure is not well controlled, implying that ARBs have renoprotective actions independent of changes in blood pressure.   * effectiveness in controlling UAE [urinary albumin excretion] in cases in which blood pressure is not well controlled, implying that ARBs have renoprotective actions independent of changes in blood pressure.
-  * ability to actively control proteinuria and stabilize kidney function in children, providing an alternative to more toxic therapies, especially corticosteroids, in children with glomerular disorders such as those associated with obesity.(({{pubmed>long:17299000}})) +  * ability to actively control proteinuria and stabilize kidney function in children, providing an alternative to more toxic therapies, especially corticosteroids, in children with glomerular disorders such as those associated with obesity.(({{pmid>long:17299000}})) 
-  * formation of a dosage-dependent, anti-inflammatory effect on the kidneys that is mediated by suppression of NF-kappaB activation and chemokine expression.(({{pubmed>long:17287430}})) +  * formation of a dosage-dependent, anti-inflammatory effect on the kidneys that is mediated by suppression of NF-kappaB activation and chemokine expression.(({{pmid>long:17287430}})) 
-  * ability to retard the progression of advanced renal insufficiency.(({{pubmed>long:16636517}})) +  * ability to retard the progression of advanced renal insufficiency.(({{pmid>long:16636517}})) 
-  * effective slowing of the progression of chronic allograft nephropathy (CAN)(({{pubmed>long:16422249}}))+  * effective slowing of the progression of chronic allograft nephropathy (CAN)(({{pmid>long:16422249}}))
  
  
Line 86: Line 92:
 ==== Animal studies ==== ==== Animal studies ====
  
-[[http://hdl.handle.net/1807/96258|.Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.]]+[[https://hdl.handle.net/1807/96258|.Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ.]]
  
-Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed>long:16985512}}))+Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pmid>long:16985512}}))
  
  
-Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed>long:16755152}}))+Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pmid>long:16755152}}))
  
 {{tag>kidneys  Science}} {{tag>kidneys  Science}}
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
Line 106: Line 113:
  
 "Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?" "Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?"
-http://www.ncbi.nlm.nih.gov/pubmed/18695383+https://www.ncbi.nlm.nih.gov/pubmed/18695383
  
  
Line 127: Line 134:
  
  
-===== References======+===== References======</nodisp> 
home/protocol/olmesartan/kidney_disease.1565729167.txt.gz · Last modified: 08.13.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.